IRVINE, Calif., June 02, 2022 (GLOBE NEWSWIRE) — Eledon Prescription drugs, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused scientific stage biopharmaceutical firm dedicated to the event of progressive and impactful remedies for organ and cell transplantation, autoimmune situations, and neurodegenerative illness, right this moment introduced that David-Alexandre C. Gros, Chief Govt Officer, will current an organization overview on the Jefferies Healthcare Convention on Thursday, June 9, 2022 at 3:30 p.m. ET. The convention will likely be going down June 8-10, 2022 in New York Metropolis.
To register prematurely for the presentation webcast, join right here.
A webcast replay will likely be accessible following the stay session on the Occasions web page of the Buyers part on the Firm’s web site at https://ir.eledon.com/events-and-presentations/occasions.
About Eledon Prescription drugs and tegoprubart (previously AT-1501)
Eledon Prescription drugs is a scientific stage biotechnology firm utilizing its experience in concentrating on the CD40 Ligand (CD40L, additionally referred to as CD154) pathway to develop potential remedies for individuals requiring an organ or cell-based transplant, residing with autoimmune illness, or residing with ALS. The corporate’s lead compound in improvement is tegoprubart, an anti-CD40L antibody with excessive affinity for CD40 Ligand, a well-validated organic goal with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For extra info, please go to the corporate’s web site at www.eledon.com.
Comply with Eledon Prescription drugs on social media: LinkedIn; Twitter